Brief: Context Therapeutics And Lonza Enter Manufacturing Agreement For Bispecific Antibody Targeting Claudin 6-Positive Cancers
09/01/2023 13:24
Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS AND LONZA ENTER MANUFACTURING
AGREEMENT FOR
BISPECIFIC ANTIBODY TARGETING CLAUDIN 6-POSITIVE CANCERS
* CONTEXT THERAPEUTICS - LONZA WILL PROVIDE
MANUFACTURABILITY
ASSESSMENT, GENE AND CELL LINE CONSTRUCTION, AND PROCESS
DEVELOPMENT
Source text for Eikon: ID:nGNX1t83YH
Further company coverage: CNTX.O
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202